Placental-derived stem cell therapy - Celularity

Drug Profile

Placental-derived stem cell therapy - Celularity

Alternative Names: HPDSC; Human placenta-derived stem cells; PSC-100; UCB + HPDSC; UCB and HPDSC

Latest Information Update: 21 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation; Human Longevity
  • Developer Celgene Corporation; Celularity; Human Longevity; New York Medical College
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological disorders; Haematological malignancies
  • Preclinical Inflammation
  • Research Muscular atrophy

Most Recent Events

  • 07 Apr 2016 Phase-I development for malignant and non-malignant Haematological disorders, and early research for Muscular atrophy are ongoing in USA
  • 11 Aug 2014 Celgene Cellular Therapeutics and Human Longevity enter into license agreement to develop and co-commercialise PSC 100
  • 11 Aug 2014 Early research in Muscular atrophy in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top